JPMorgan Chase & Co. Has Lowered Expectations for Equifax (NYSE:EFX) Stock Price

Equifax (NYSE:EFX) had its price objective cut by equities research analysts at JPMorgan Chase & Co. from $260.00 to $230.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the credit services provider’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 17.64% from the company’s current price.

Several other research analysts have also recently commented on EFX. Barclays reduced their target price on Equifax from $240.00 to $215.00 and set an “equal weight” rating for the company in a research report on Thursday. Royal Bank Of Canada set a $220.00 target price on shares of Equifax in a research report on Thursday. Wells Fargo & Company dropped their price target on shares of Equifax from $265.00 to $240.00 and set an “overweight” rating for the company in a research report on Thursday. BMO Capital Markets set a $195.00 price target on shares of Equifax in a research note on Thursday. Finally, Needham & Company LLC lowered their price objective on Equifax from $295.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $240.33.

Equifax Price Performance

Shares of Equifax stock opened at $195.52 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 0.60 and a quick ratio of 0.74. The company has a market cap of $23.93 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 1.98 and a beta of 1.55. The firm has a fifty day moving average price of $212.79 and a two-hundred day moving average price of $227.58. Equifax has a fifty-two week low of $166.02 and a fifty-two week high of $281.03.

Equifax (NYSE:EFX) last announced its quarterly earnings data on Wednesday, February 4th. The credit services provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $2.05 by $0.04. Equifax had a net margin of 10.87% and a return on equity of 19.27%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the business earned $2.12 earnings per share. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Equifax has set its FY 2026 guidance at 8.300-8.700 EPS and its Q1 2026 guidance at 1.630-1.730 EPS. Analysts expect that Equifax will post 7.58 EPS for the current year.

Institutional Investors Weigh In On Equifax

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. bought a new stake in shares of Equifax during the fourth quarter worth $25,000. Country Trust Bank bought a new stake in Equifax during the 2nd quarter worth about $26,000. Lodestone Wealth Management LLC acquired a new stake in Equifax in the 4th quarter valued at about $29,000. Ameritas Advisory Services LLC bought a new position in shares of Equifax in the second quarter worth about $31,000. Finally, True Wealth Design LLC lifted its position in shares of Equifax by 64.4% during the fourth quarter. True Wealth Design LLC now owns 148 shares of the credit services provider’s stock worth $32,000 after purchasing an additional 58 shares in the last quarter. 96.20% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Equifax

Here are the key news stories impacting Equifax this week:

• Positive Sentiment: Q4 beat and constructive guidance: Equifax reported a Q4 beat on revenue and EPS, and set FY2026 guidance (EPS 8.30–8.70) and Q1 guidance that signal continued top-line growth — a primary reason investors are bidding the stock up. Read More.
• Positive Sentiment: AI expansion and government segment momentum: Management highlighted AI-powered product expansion and a rebound in the government business, which supports longer-term revenue upside and premium valuation expectations. Read More.
• Positive Sentiment: VantageScore traction and partnerships: Execs noted VantageScore adoption gains and a new partnership (Gen + Equifax) to broaden consumer financial solutions — both support recurring data/licensing growth. Read More. | Read More.
• Neutral Sentiment: Analysts still bullish despite cuts: Several firms cut price targets after the quarter but maintained Buy/Overweight/Outperform ratings (JPM, RBC, Wells, Needham, Morgan Stanley), leaving meaningful upside in consensus PTs even after downgrades. These mixed signals can mute momentum but keep analyst support. Read More.
• Negative Sentiment: Regulatory/media scrutiny: A New York Times piece highlights senators accusing Equifax of “price‑gouging” on Medicaid services — elevated regulatory and political risk that could pressure valuation or lead to contract/price scrutiny in public-sector work. Read More.

About Equifax

Equifax Inc (NYSE: EFX) is a global data, analytics and technology company that specializes in consumer and commercial credit reporting, decisioning tools and identity solutions. Headquartered in Atlanta, Georgia, Equifax is one of the three major consumer credit reporting agencies in the United States and provides credit information and related services to lenders, employers, governments and consumers worldwide.

The company’s offerings include consumer credit reports and scores, credit monitoring and identity protection services, and a range of business-oriented products for risk management, fraud detection and compliance.